Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

NCT02971293 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease COPD

Interventions

DRUG: AZD8871 100 µg
DRUG: AZD8871 600 µg
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]